PM360 Magazine’s Post

Future Pharma 2024 is around the corner! Adam Alfi and Mai Shafei are attending the World’s Leading Pharma Commercialization Event. Stay tuned for more insights from the event! #futurepharma2024

Two weeks ago, over 60 of us came together in NYC for a fantastic day of discussion at the Bioethics International Roundtable as leaders from across the biopharmaceutical industry. As always, the event was inspiring as we explored key topics such as clinical trial diversity, patient centricity, access to medicines globally, and the rapidly evolving focus on ESG in our industry. I was particularly inspired by the discussion focused on sharing individual results to clinical trial participants, a topic that has been a passion for me since my GSK days where I was deeply involved in the development of plain language summaries, internally and externally, as it was a new component of clinical trial transparency spurred on by the EU Clinical Trial Regulation requirement. From that point, it simply made sense to move from sharing aggregate results to sharing individual results. So proud to represent Legacy Health Strategies in this forum and to have developed the capability to operationalize sharing of individual and aggregate results via a digital communication platform connecting sponsors and participants, before, during and after clinical trials. Looking forward to collaborating further to ensure the industry lives up to its full potential for good! - CEO Jessica Scott, MD, JD #BioethicsInternational #BEI #HealthEquity #ClinicalTrials #PatientEngagement #ESG #Transparency #LegacyHealthStrategies #DrugDevelopment #RoundTable #Pharma #NYC

On both sides of the Atlantic pharma companies are presenting cases to the courts and to national regulators that the innovation cash pipelines will be disrupted, forcing them to either cut back and delay launches or move operations to Asia Pacific or Latin America. Find out more in our newly published whitepaper featuring industry experts: ·      Christoph Glaetzer, Dipl.Kfm., Chief Global Value and Access at Johnson & Johnson Innovative Medicine ·      Ricardo Werner Marek, President Europe & Canada at Takeda ·      Andy Powrie-Smith, Executive Director, Communications & Partnerships at EFPIA - European Federation of Pharmaceutical Industries and Associations Access the full whitepaper here: https://bit.ly/3Vh46Y2

On the cross-country flight home from a wonderful and busy BIO International Convention, I spent some time reflecting on three years here at the National Pharmaceutical Council. I still remember flying to DC as the brand-new President and CEO of the organization in June 2021 – a trip that simultaneously feels like yesterday and a lifetime ago, given the changes in the industry, health policy, and research environment. The work of NPC has never been more relevant — or more important. We have a great team, and this team appreciates the challenges we face. Here are three reflections I’d offer for anyone interested in the future of innovation. • To meet the challenges of today and tomorrow, NPC has built new capabilities that allow us to build on our 70-year legacy as we conduct rigorous, policy-relevant research and communicate it with impact. I invite you to learn more about the value we provide to NPC members and the benefits member companies experience. https://lnkd.in/etCWVqTE • NPC’s research informs many of the important policy conversations going on right now. To stay up to date on our latest, I hope you subscribe to the NPC This Week Newsletter to get a weekly look-ahead at the policy, research, and industry conversations that matter to the future of biopharmaceutical innovation. https://lnkd.in/eBAj7B_B  • I’m proud of the team at NPC and what we’ve accomplished — while recognizing the challenges in front of us. If you’d like to see more of our recent research, analysis, and work, check out our 2023 Annual Report. https://lnkd.in/eB6u2nWd  I’ve loved every minute of the past three years and look forward to many more. These aren’t challenges we can solve alone, and it has never been more important for drugmakers, payers, and policymakers to understand the ecosystem and work together for the benefit of patients. If we haven’t spoken in a while, I’d love to hear from you, whether in the DMs, email, or phone.  #pharma #innovation #healthpolicy

Following the launch of the Harnessing the Full Potential of Real-World Data Enhance Clinical Trials Roundtable Discussion (12 June 2024, 11am-12pm EST/4pm-5pm BST, 60 minutes), we had the opportunity to sit down with the content director Prishu Kagra to discuss the key themes of the session. Specialists from leading #Pharma organizations Sanofi, Novartis, GSK, AstraZeneca and Parexel will be sharing their best practice use cases for implementing real-world data and evidence to drive innovation, improve patient outcomes, and advance healthcare delivery in clinical trials. Swipe below to see the key themes of the upcoming virtual roundtable >>> Register FREE: https://lnkd.in/eSPseiVg #AMGWorld #Technology #ClinicalOperations #ClinicalInnovation #Digitalization #RealWorldData

#processanalyticaltechnology is quickly accelerating in biopharmaceutical applications. Join the ONLY industry meeting discussing PAT applications in pharma R&D and GMP manufacturing environments, and how we can realize real time process control and monitoring. 📈 Workshops include Exploring QbD, Continuous Improvement, Real-Time Monitoring & PAT Integration in Manufacturing and Development Strategies & Machine Learning for Application in Cross-Manufacturing Environment with Sanofi 📈 With the recent boom in #AI & #machinelearning don't miss sessions on predictive modelling approaches and machine learning advances with The Janssen Pharmaceutical Companies of Johnson & Johnson Moderna and Novo Nordisk 📈 As process understanding and manufacturing remains a major bottleneck for #cellandgenetherapy join Bristol Myers Squibb in Utilizing Process Analytical Technology (PAT) for Identification of Critical Process Parameters (CPPs) & Critical Quality Attributes (CQAs) in the Field of Cell Gene Therapy Join us here whilst registration cost is at it's lowest https://ter.li/t8sksd December 5th - 7th in Boston, MA.

Today in the spotlight ✨ Janssen: Collaboration for a healthy future ✨ Michel van Agthoven | Head Janssen/Johnson & Johnson Campus The Netherlands: “𝘛𝘩𝘦 𝘋𝘶𝘵𝘤𝘩 𝘓𝘪𝘧𝘦 𝘚𝘤𝘪𝘦𝘯𝘤𝘦 & 𝘏𝘦𝘢𝘭𝘵𝘩 𝘦𝘤𝘰𝘴𝘺𝘴𝘵𝘦𝘮 𝘪𝘴 𝘢𝘵𝘵𝘳𝘢𝘤𝘵𝘪𝘷𝘦, 𝘣𝘦𝘤𝘢𝘶𝘴𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘱𝘳𝘦𝘴𝘦𝘯𝘤𝘦 𝘰𝘧 𝘩𝘪𝘨𝘩𝘭𝘺 𝘦𝘥𝘶𝘤𝘢𝘵𝘦𝘥 𝘵𝘢𝘭𝘦𝘯𝘵, 𝘵𝘰𝘱 𝘴𝘤𝘪𝘦𝘯𝘤𝘦 𝘢𝘯𝘥 𝘢 𝘷𝘪𝘣𝘳𝘢𝘯𝘵 𝘣𝘪𝘰𝘵𝘦𝘤𝘩 𝘴𝘵𝘢𝘳𝘵-𝘶𝘱 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺 - 𝘢𝘭𝘭 𝘤𝘭𝘰𝘴𝘦 𝘵𝘰 𝘦𝘢𝘤𝘩𝘰𝘵𝘩𝘦𝘳. 𝘛𝘩𝘪𝘴 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘴 𝘢𝘮𝘱𝘭𝘦 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘪𝘦𝘴 𝘧𝘰𝘳 𝘤𝘳𝘰𝘴𝘴-𝘧𝘦𝘳𝘵𝘪𝘭𝘪𝘻𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯. 𝘞𝘦 𝘢𝘳𝘦 𝘤𝘰𝘮𝘮𝘪𝘵𝘵𝘦𝘥 𝘵𝘰 𝘧𝘶𝘦𝘭 𝘵𝘩𝘪𝘴 𝘦𝘤𝘰𝘴𝘺𝘴𝘵𝘦𝘮 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘰𝘶𝘳 𝘱𝘢𝘳𝘵𝘯𝘦𝘳𝘴𝘩𝘪𝘱𝘴 𝘸𝘪𝘵𝘩 𝘩𝘰𝘴𝘱𝘪𝘵𝘢𝘭𝘴, 𝘶𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘪𝘦𝘴, 𝘢𝘯𝘥 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘪𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦𝘴 𝘴𝘶𝘤𝘩 𝘢𝘴 𝘛𝘕𝘖, 𝘙𝘢𝘥𝘣𝘰𝘶𝘥 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘢𝘯𝘥 𝘙𝘢𝘥𝘣𝘰𝘶𝘥 𝘜𝘔𝘊, 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘰𝘧 𝘓𝘦𝘪𝘥𝘦𝘯 𝘢𝘯𝘥 𝘓𝘜𝘔𝘊. 𝘞𝘦 𝘧𝘪𝘳𝘮𝘭𝘺 𝘣𝘦𝘭𝘪𝘦𝘷𝘦 𝘵𝘩𝘢𝘵 𝘣𝘺 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯, 𝘸𝘦’𝘳𝘦 𝘤𝘳𝘦𝘢𝘵𝘪𝘯𝘨 𝘢 𝘧𝘶𝘵𝘶𝘳𝘦 𝘸𝘩𝘦𝘳𝘦 𝘥𝘪𝘴𝘦𝘢𝘴𝘦 𝘪𝘴 𝘢 𝘵𝘩𝘪𝘯𝘨 𝘰𝘧 𝘵𝘩𝘦 𝘱𝘢𝘴𝘵.” Janssen is one of the showcase companies in our bidbook 'Welcome to the Netherlands: Europe's Connected Life Sciences & Health Metropolis'. Together, as pharmaceutical company of Johnson & Johnson, Janssen regards end-to-end activities for medicines and vaccines from lab to patient. This covers research & development at Janssen Vaccines & Prevention, manufacturing at Janssen Biologics, and distribution and marketing at Janssen the Netherlands. Want to read more about Janssen and other companies located in The Netherlands? Have a look in our bidbook and find out why the Netherlands is an attractive place for innovative business: https://lnkd.in/eQYeTd8J TNO Radboud University Radboudumc Universiteit Leiden Leiden University Medical Center The Janssen Pharmaceutical Companies of Johnson & Johnson Janssen Europe, Middle East & Africa (EMEA)

It might surprise people that most primary and secondary CI knowledge actually sits in the archives and is often not used in strategy documents (original form) such as IPS (Integrated Product Strategy, a 5-year long-term brand plan) or War Games (scenario plans). At AdametNext, we understand the strategic requirements of marketing teams; hence, our deliverables are always 90 to 100% ready for strategic meetings. This is only possible due to the prior inside-out pharma brand management knowledge we gained while working with the CXO or brand directors.